Carl June, Sens. Blunt and Casey to receive AACI awards

Janet Woodcock, Paul Kim join Friends’ board of directors

Janet WoodcockPaul T. KimJanet Woodcock, former director of the Center for Drug Evaluation and Research at FDA, and Paul T. Kim, principal of Kendall Square Policy Strategies LLC, were appointed to the board of directors at Friends of Cancer Research.

January 24, 2025

In Brief

University Hospitals and Case Western Reserve fund magnetic resonance fingerprinting research

The Collaborative Science Pilot Awards, a program supported by the Case Western Reserve University—University Hospitals Joint Strategic Leadership Committee, awarded five research teams $50,000 with the possibility of receiving additional funding as scientific milestones are met.

January 24, 2025

Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.

January 24, 2025

Clinical Roundup

DFCI researchers use PET imaging to detect body inflammation

Researchers at Dana-Farber Cancer Institute developed a method to detect inflammation in the body using positron emission tomography imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types.

January 24, 2025

Clinical Roundup

Deadly dog cancer reveals clues for improved treatment, UF study finds

Researchers at the University of Florida College of Veterinary Medicine and the UF Health Cancer Center have identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma, a discovery that could lead to better treatments for both dogs and humans with similar cancers.

January 24, 2025

Drugs & Targets

FDA grants RP1 BLA priority review for advanced melanoma

FDA has accepted the Biologics License Application from Replimune Group Inc. for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for patients with advanced melanoma.

January 24, 2025

Carl June, Sens. Blunt and Casey to receive AACI awards

YOU MAY BE INTERESTED IN

Janet Woodcock, Paul Kim join Friends’ board of directors

University Hospitals and Case Western Reserve fund magnetic resonance fingerprinting research

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

DFCI researchers use PET imaging to detect body inflammation

Deadly dog cancer reveals clues for improved treatment, UF study finds

FDA grants RP1 BLA priority review for advanced melanoma

Renew today!

Subscriber content

Never miss an issue!

Login